| Literature DB >> 35517814 |
Nancy Ortiz-Mendoza1, Eva Aguirre-Hernández1, Itzi Fragoso-Martínez2, María Eva González-Trujano3, Francisco A Basurto-Peña4, Martha J Martínez-Gordillo5.
Abstract
Salvia is the most diverse genus within the mint family (Lamiaceae), many of its species are well-known due to their medicinal and culinary uses. Most of the ethnopharmacological and phytochemical studies on Salvia are centred on species from the European and Asian clades. However, studies about the most diverse clade, the Neotropical sages (Salvia subgenus Calosphace; 587 spp.), are relatively scarce. This review aims to compile the information on the traditional medicinal uses, pharmacological and phytochemistry properties of the Neotropical sages. To do so, we carried out a comprehensive review of the articles available in different online databases published from the past to 2022 (i.e., PubMed, Scopus, and Web of Science, among others) and summarized the information in tables. To uncover phylogenetic patterns in the distribution of four different groups of metabolites (mono-, sesqui-, di-, and triterpenes), we generated presence-absence matrices and plotted the tip states over a dated phylogeny of Salvia. We found several studies involving Mexican species of Salvia, but only a few about taxa from other diversity centres. The main traditional uses of the Mexican species of Calosphace are medicinal and ceremonial. In traditional medicine 56 species are used to treat diseases from 17 categories according to the WHO, plus cultural-bound syndromes. Pharmacological studies reveal a wide range of biological properties (e.g., antinociceptive, anti-inflammatory, anxiolytic, cytotoxic, and antidiabetic, etc.) found in extracts and isolated compounds of 38 Neotropical sages. From extracts of these species, at least 109 compounds have been isolated, identified and evaluated pharmacologically; 73 of these compounds are clerodanes, 21 abietanes, six flavonoids, five sesquiterpenoids, and four triterpenoids. The most characteristic metabolites found in the Neotropical sages are the diterpenes, particularly clerodanes (e.g., Amarisolide A, Tilifodiolide), that are found almost exclusively in this group. The Neotropical sages are a promising resource in the production of herbal medication, but studies that corroborate the properties that have been attributed to them in traditional medicine are scarce. Research of these metabolites guided by the phylogenies is recommended, since closely related species tend to share the presence of similar compounds and thus similar medicinal properties.Entities:
Keywords: abietane; bioactive compounds; clerodane; diterpene; mexican traditional medicine
Year: 2022 PMID: 35517814 PMCID: PMC9061990 DOI: 10.3389/fphar.2022.867892
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Selected species of Neotropical sages (Salvia subgenus Calosphace) that have been studied from phytochemical and/or ethnopharmacological perspectives. (A) Salvia carnea, (B) S. coccinea, (C) S. connivens, (D) S. corrugata, (E) S. elegans, (F) S. gesneriiflora, (G) S. hispanica (chia), (H) S. iodantha, (I) S. lavanduloides, (J) S. longispicata, (K) S. mexicana, (L) S. occidentalis, (M) S. purpurea, (N) S. sessei, (O) S. urica. Photo credits Gerardo Salazar.
FIGURE 2Medicinal uses reported for species of Salvia subgenus Calosphace in Mexico. (A) Number of species used to tackle diseases from different categories according to the WHO (WHO. ICD-11, 2021), (B) Number of mentions and disease categories associated with different species of Neotropical sages in Mexican traditional medicine. Abbreviations of the disease categories are as follows: Digestive system (diseases of the digestive system); symptoms and signs (Symptoms, signs or clinical findings, not elsewhere classified); pregnancy, childbirth (Pregnancy, childbirth or the puerperium); *cultural (Cultural-bound syndromes, not included in the WHO classification); musculoskeletal system (Diseases of the musculoskeletal system or connective tissue); infectious/Parasitic (Certain infectious or parasitic diseases); genitourinary (Diseases of the genitourinary system); injury, poisoning (Injury, poisoning or certain other consequences of external causes); nervous system (Diseases of the nervous system); skin (Diseases of the skin); endocrine (Endocrine, nutritional or metabolic diseases); respiratory system (Diseases of the respiratory system); ear (Diseases of the ear or mastoid process); sleep/wake (Sleep-wake disorders); visual system (Diseases of the visual system); neoplasms (Neoplasms); circulatory system (Diseases of the circulatory system); perinatal period (Certain conditions originating in the perinatal period).
Pharmacological activities for species of Salvia subgenus Calosphace from Mexico.
| Species (Scientific name) | Extract or compound(s) | Part of the Plant | Pharmacological Activities | Positive Control | References |
|---|---|---|---|---|---|
|
| Aqueous extract | Leaves | DPPH: 80% inhibition at 160 μg/ml | Ascorbic acid |
|
| Anti-diabetic. Albino Wistar rats (150–200 g) | Glibenclamide (10 mg/kg, p.o.) | ||||
|
| Salvileucantholide | Aerial parts | HCT116 (IC50 = 32.61 μM); BT474 (IC50 = 25.02 μM); HepG2 (IC50 = 37.35 μM) | Hsp90 luciferase refolding |
|
| Salvileucantholide; 3β-methoxyisopuberulin; dugesin B | Acetylcholinesterase inhibitory activity (IC50 = 50.55; 32.2; 22.13 μM) | n.i | |||
| Leucansalvialin G and J | Neurotrophic activities on PC12 cells (Differentiation rate 9.52%) | Nerve Growth Factor (Differentiation rate 18.43%) |
| ||
| Salvileucalin B | Cytotoxic activity against A549 and HT-29 cells with IC50 5.23 and 1.88 μg/ml, respectively | n.i |
| ||
| Essential oil | Inhibitory activity of the enzyme butyrylcholinesterase (IC50 = 32.60 μg/ml) | Donepezil (IC50 3.6 μg/ml) |
| ||
| Salviandulin E | Antitrypanosomal activity against | Pentamidine (IC50 0.0017 μg/ml), suramin (IC50 1.58 μg/ml), eflornithine (IC50 2.27 μg/ml) |
| ||
|
| Aqueous extract | Aerial parts |
| Nisin: |
|
| DPPH, ferric reducing power, TBARS (EC50 = 10.0; 34.0; 26.2 μg/ml) | Ascorbic acid, butylated hydroxy anisole and trolox (EC50 = 6.68; 16.1; 23.0 μg/ml) | ||||
| Antiinflammatory activity: NO production inhibition | Dexamethasone (EC50 = 66.3 μg/ml) | ||||
| HepG2 (EC50 = 52.4 μg/ml); HeLa (EC50 = 61.0 μg/ml); MCF-7 (EC50=66.2 μg/ml) | Ellipticine (EC50 = 1.0; 2.0; 1.0 μg/ml) | ||||
|
| Carnosic acid 12-methylether | Aerial parts | Antibacterial activity ( | Cefuroxime sodium |
|
| Microphyllandiolide; salvimicrophyllin B; salvimicrophyllin D |
| Metronidazole (IC50 = 0.23 µM); (IC50 1.22 µM); Emetine (IC50 = 0.83 µM); (IC50 2.18 µM) |
| ||
| Essential oil | Leaves | Antioxidant activity β-carotene/linoleic acid (IC50 = 770 μg/ml) | Thymol (IC50 = 714 μg/ml) |
| |
| Hexane extract | Aerial parts | Insecticidal against | n.i |
| |
| Ethanol extract (95%) | Leaves | -Neuroprotective effect in the memory impairment evaluated in male albino rats Step-through passive avoidance (300 mg/kg, p.o.), Morris water maze (150 and 300 mg/kg, p.o.) | Donezepil (0.5 mg/kg, i.p.) |
| |
| -Cholinergic dysfunction via acetyl cholinesterase activity (150 and 300 mg/kg, p.o.) | |||||
| -Oxidative stress markers: catalase activity, reduced glutathione level and lipid peroxidation level (300 mg/kg, p.o.) | |||||
|
| Linearolactone; polystachyne E | Aerial parts |
| Metronidazole (IC50 = 0.23; 1.22 µM) Emetine (IC50 = 0.83; 2.18 µM) |
|
| Ethanol extract | Neuroprotective: | Resveratrol |
| ||
|
| |||||
| Antioxidant. OH (IC50 = 154.18 μg/ml); O2 − (IC50 = 118.97 μg/ml); ROO- (IC50 = 18.21 μg/ml) | Resveratrol: OH (IC50 = 30.02 μg/ml); O2- (IC50 = 28.28 μg/ml); ROO (IC50 = 18.21 μg/ml) | ||||
| Salvifiline A; 15-epi-salvifiline A | Leaves | Induced collagen (COL1A1) transcription at 0.27 µM. Human dermal fibroblasts | Ascorbic acid (100 µM) |
| |
| Polystachyne G; 15-epi-polystachyne G | Stimulated expression of the elastin gene at 25.6 µM |
DPPH, 2,2-diphenyl-1-picrilhidrazil; EC50, Half-maximal effective concentration; IC50, Half-maximal inhibitory concentration; LC50, Half-maximal lethal concentration; MBC, minimal bactericidal concentration; MIC, minimum inhibitory concentration; n.i., non-information; TBARS, thiobarbituric acid reactive substance.
FIGURE 3Bioactive compounds found in Salvia subgenus Calosphace. (A) Monoterpenoids, (B) Sesquiterpenoids, (C) Abietanes, (D) Clerodanes, (E) Triterpenoids, (F) Polyphenols.
FIGURE 4Distribution of different types of terpenes in the Neotropical sages (Salvia subgen. Calosphace) and their related lineages. The lineages of Salvia s.l. are color-coded. An asterisk (*) marks the Fulgentes subclade, recovered as part of the core Calosphace clade in other phylogenies (i.e., Jenks et al., 2013; Fragoso-Martínez et al., 2018).